Table 4.

Predictive factors associated with 14-week CAI remission (univariate analysis)

Characteristic	14-Week CAIa remission
	Odds ratio	95 % CIb	p
Baseline
Male sex	1.06	0.42, 2.64	0.901
Age < 39.5 years	0.62	0.25, 1.48	0.277
Weight < 56.0 kg	0.86	0.36, 2.07	0.735
Smoker	2.07	0.42, 15.11	0.383
Colonic area involved
Extensive	0.40	0.10, 1.29	0.129
Concomitant medications
Corticosteroids (oral)	1.27	0.49, 3.28	0.621
5-Aminosalicylates (oral)	2.02	0.79, 5.35	0.144
Immunomodulators	0.67	0.28, 1.61	0.373
Azathioprine	0.68	0.27, 1.68	0.399
6-Mercaptopurine	0.93	0.26, 3.49	0.911
Corticosteroid-refractory disease	1.95	0.63, 6.76	0.250
Corticosteroid-dependent disease	0.80	0.33, 1.95	0.628
Mayo score ≥ 11	1.05	0.22, 5.62	0.953
CAI ≥ 12	0.77	0.20, 3.01	0.706
C-reactive protein ≤ 0.5 mg/dl	2.34	0.97, 5.83	0.059
Albumin ≥ 3.8 g/dl	1.03	0.40, 2.61	0.945
At week 2
CAI ≤ 4	5.97	2.30, 16.86	<0.001
TLc ≥ 20.7 μg/ml	2.75	1.13, 6.93	0.025
TL/CAI ≥ 3.6	5.37	2.12, 14.50	<0.001

^aCAI, clinical activity index; ^bCI, confidence interval; ^cTL, serum infliximab trough level

Logistic regression analysis

Stratified analyses by age, body weight, first TL, and first TL/CAI using median values as cutoffs. The cutoff values of other end points were their reference values